RxDoctor Payments Data

Molly Gray, DO

Family Medicine · Comanche, TXNPI 1760641187

Payments from drug & device makers

$1,378in general payments, 2019–2025

Across 72 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$319
  • AstraZeneca$188
  • Amgen$125
  • GM Pharmaceuticals, Inc.$90
  • Lilly USA, LLC$89
  • AbbVie$74
  • plus $493 from 16 others

What the payments were for

  • Food & beverage$1,378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,378 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$8,999
Medicare patients
40
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$66,647
EliquisApixaban121$55,304
JardianceEmpagliflozin116$50,821
MounjaroTirzepatide38$40,746
FarxigaDapagliflozin Propanediol38$21,889
LinzessLinaclotide33$18,774
TrulicityDulaglutide15$15,415
MyrbetriqMirabegron32$13,841
Combivent RespimatIpratropium/Albuterol Sulfate15$11,181
JanuviaSitagliptin Phosphate17$10,585
EntrestoSacubitril/Valsartan21$8,818
Potassium Chloride257$8,229
XareltoRivaroxaban27$8,058
VascepaIcosapent Ethyl19$7,317
Invega SustennaPaliperidone Palmitate12$7,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$319$66,64761 claims
Boehringer IngelheimJardiance, Combivent Respimat$16$62,002131 claims
PfizerEliquis, Premarin$52$57,653144 claims
Lilly USA, LLCMounjaro, Trulicity$89$56,16153 claims
AstraZenecaFarxiga, Symbicort$188$25,14253 claims
AbbVieLinzess$74$18,77433 claims
MerckJanuvia$29$10,58517 claims
NovartisEntresto$31$8,81821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Comanche

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →